178 related articles for article (PubMed ID: 33072987)
21. Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency.
Shih STF; Keller E; Wiley V; Farrar MA; Wong M; Chambers GM
Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892475
[TBL] [Abstract][Full Text] [Related]
22. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
24. Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation.
Thompson SG; Bown MJ; Glover MJ; Jones E; Masconi KL; Michaels JA; Powell JT; Ulug P; Sweeting MJ
Health Technol Assess; 2018 Aug; 22(43):1-142. PubMed ID: 30132754
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement.
Watt M; Mealing S; Eaton J; Piazza N; Moat N; Brasseur P; Palmer S; Busca R; Sculpher M
Heart; 2012 Mar; 98(5):370-6. PubMed ID: 22076021
[TBL] [Abstract][Full Text] [Related]
26. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
27. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
[TBL] [Abstract][Full Text] [Related]
28. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia.
Modell V; Knaus M; Modell F
Immunol Res; 2014 Oct; 60(1):145-52. PubMed ID: 24599744
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of exercise referral schemes.
Anokye NK; Trueman P; Green C; Pavey TG; Hillsdon M; Taylor RS
BMC Public Health; 2011 Dec; 11():954. PubMed ID: 22200193
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes.
Pan X; Dvortsin E; Baldwin DR; Groen HJM; Ramaker D; Ryan J; Berge HT; Velikanova R; Oudkerk M; Postma MJ
J Med Econ; 2024; 27(1):27-38. PubMed ID: 38050691
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
[TBL] [Abstract][Full Text] [Related]
34. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of School Urinary Screening for Early Detection of IgA Nephropathy in Japan.
Honda K; Akune Y; Goto R
JAMA Netw Open; 2024 Feb; 7(2):e2356412. PubMed ID: 38363568
[TBL] [Abstract][Full Text] [Related]
36. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
[TBL] [Abstract][Full Text] [Related]
37. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
38. Newborn screening for severe combined immunodeficiency: clinical and cost-effectiveness approaches.
Boyarchuk O; Yarema N; Kinash M; Chornomydz I
Pol Merkur Lekarski; 2021 Feb; 49(289):80-83. PubMed ID: 33713100
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
40. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.
Kwan A; Abraham RS; Currier R; Brower A; Andruszewski K; Abbott JK; Baker M; Ballow M; Bartoshesky LE; Bonilla FA; Brokopp C; Brooks E; Caggana M; Celestin J; Church JA; Comeau AM; Connelly JA; Cowan MJ; Cunningham-Rundles C; Dasu T; Dave N; De La Morena MT; Duffner U; Fong CT; Forbes L; Freedenberg D; Gelfand EW; Hale JE; Hanson IC; Hay BN; Hu D; Infante A; Johnson D; Kapoor N; Kay DM; Kohn DB; Lee R; Lehman H; Lin Z; Lorey F; Abdel-Mageed A; Manning A; McGhee S; Moore TB; Naides SJ; Notarangelo LD; Orange JS; Pai SY; Porteus M; Rodriguez R; Romberg N; Routes J; Ruehle M; Rubenstein A; Saavedra-Matiz CA; Scott G; Scott PM; Secord E; Seroogy C; Shearer WT; Siegel S; Silvers SK; Stiehm ER; Sugerman RW; Sullivan JL; Tanksley S; Tierce ML; Verbsky J; Vogel B; Walker R; Walkovich K; Walter JE; Wasserman RL; Watson MS; Weinberg GA; Weiner LB; Wood H; Yates AB; Puck JM; Bonagura VR
JAMA; 2014 Aug; 312(7):729-38. PubMed ID: 25138334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
